Cytokinetics, Inc.

How big is Cytokinetics, Inc.?

As of Jun 18, Cytokinetics, Inc. has a market capitalization of $3.89 billion, with recent net sales of $19.22 million and a net profit of -$615.26 million. The company reported shareholder's funds of -$135.37 million and total assets of $1.40 billion as of Dec 24.

Market Cap: As of Jun 18, Cytokinetics, Inc. has a market capitalization of 3,886.16 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cytokinetics, Inc. reported net sales of 19.22 million and a net profit of -615.26 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -135.37 million and total assets of 1,401.67 million.

What does Cytokinetics, Inc. do?

Cytokinetics, Inc. is a late-stage biopharmaceutical company focused on developing muscle activators for diseases affecting muscle performance. As of March 2025, it has a market cap of approximately $3.89 billion, with recent net sales of $2 million and a net loss of $161 million.

Overview: <BR>Cytokinetics, Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators for the treatment of diseases where muscle performance is compromised, operating within the Pharmaceuticals & Biotechnology industry and categorized as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -161 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,886.16 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.98 <BR>Return on Equity: 225.39% <BR>Price to Book: -14.59<BR><BR>Contact Details: <BR>Address: 280 E Grand Ave, SOUTH SAN FRANCISCO CA 94080-4808 <BR>Tel: ['1 650 6243000', '1 650 6243060'] <BR>Fax: 1 650 6243010 <BR>Website: http://cytokinetics.com/

Should I buy, sell or hold Cytokinetics, Inc.?

Who are in the management team of Cytokinetics, Inc.?

As of March 2022, the management team of Cytokinetics, Inc. includes Dr. Leonard Patrick Gage (Independent Chairman), Mr. Robert Blum (President and CEO), and several independent directors: Mr. Robert Califf, Mr. Santo Costa, Dr. John Henderson, Dr. Edward Kaye, and Ms. B. Lynne Parshall. This team is responsible for the company's strategic direction and governance.

As of March 2022, the management team of Cytokinetics, Inc. includes the following individuals:<BR><BR>- Dr. Leonard Patrick Gage, Independent Chairman of the Board<BR>- Mr. Robert Blum, President, Chief Executive Officer, and Director<BR>- Mr. Robert Califf, Independent Director<BR>- Mr. Santo Costa, Independent Director<BR>- Dr. John Henderson, Independent Director<BR>- Dr. Edward Kaye, Independent Director<BR>- Ms. B. Lynne Parshall, Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Is Cytokinetics, Inc. overvalued or undervalued?

As of August 2, 2017, Cytokinetics, Inc. is considered overvalued and risky due to negative valuation metrics and underperformance compared to industry peers, with a significant 5-year return lagging behind the S&P 500.

As of 2 August 2017, the valuation grade for Cytokinetics, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its significant negative valuation metrics, including a Price to Book Value of -14.48, an EV to EBIT of -6.36, and an EV to EBITDA of -6.47. These ratios suggest that the company's financial performance is not only lacking but also worse than its peers.<BR><BR>In comparison to its industry, Cytokinetics is underperforming relative to companies like ACADIA Pharmaceuticals, which has a P/E ratio of 19.28 and an EV to EBITDA of 33.99, indicating a more favorable valuation. Additionally, Corcept Therapeutics is considered very expensive with a P/E of 60.03, further highlighting Cytokinetics' struggles. Recent stock performance shows that while Cytokinetics had a 5-year return of 126.05%, it has significantly underperformed against the S&P 500 over the same period, which returned 231.64%. This trend reinforces the notion that Cytokinetics is currently overvalued.

Is Cytokinetics, Inc. technically bullish or bearish?

As of October 31, 2025, Cytokinetics, Inc. shows a bullish technical trend despite a bearish RSI, having outperformed the S&P 500 year-to-date with a 26.74% return, though it lags over the 1-year and 3-year periods.

As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The weekly MACD and daily moving averages indicate a bullish stance, while the weekly RSI is bearish, suggesting some divergence in momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. The KST shows bullish momentum weekly but is bearish monthly, indicating mixed signals. Overall, the technical stance is bullish but with some caution due to the bearish RSI. <BR><BR>In terms of performance, Cytokinetics has outperformed the S&P 500 year-to-date with a return of 26.74% compared to 16.30%, but it lags over the 1-year and 3-year periods.